載入中
NASDAQHealthcareBiotechnology
最新資料
US$38.23
−US$2.05 · -5.09%
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
前收盤價
US$38.23
−US$2.05 · -5.09%
盤後
US$38.40
+US$0.17 · +0.44%
10月12日 下午7:30 ET
盤中時間採用ET。市場資料可能有所延遲。
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
日內區間
目前US$38.23
52週區間
目前US$38.23
盤中時間採用ET。市場資料可能有所延遲。
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
日內區間
目前US$38.23
52週區間
目前US$38.23
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 8.68億 USD | 7.15億 USD | 5.82億 USD | 4.38億 USD | 3.05億 USD |
| 銷貨成本 | 1.98億 USD | 1.57億 USD | 1.21億 USD | 8348.1萬 USD | 5551.8萬 USD |
| 毛利 | 6.7億 USD | 5.58億 USD | 4.61億 USD | 3.54億 USD | 2.5億 USD |
| 研究與開發 | 1.9億 USD | 1.46億 USD | 7606.3萬 USD | 7088.6萬 USD | 3036.7萬 USD |
| 銷售、一般及管理費用 | 2.72億 USD | 2.21億 USD | 1.93億 USD | 1.63億 USD | 1.32億 USD |
| 營業費用 | 4.62億 USD | 3.67億 USD | 2.69億 USD | 2.34億 USD | 1.62億 USD |
| 利息收入 | 2192.4萬 USD | 1854.2萬 USD | 1473萬 USD | 312.6萬 USD | 22.4萬 USD |
| 利息支出 | 1464.9萬 USD | 1749.6萬 USD | 2375.7萬 USD | 1879.5萬 USD | 2419.4萬 USD |
| 折舊和攤銷 | 2533.5萬 USD | 2411.2萬 USD | 2435.9萬 USD | 2338.5萬 USD | 1884萬 USD |
| 營業利益 | 2.08億 USD | 1.91億 USD | 1.92億 USD | 1.2億 USD | 8752.8萬 USD |
| 淨利 | 1.59億 USD | 1.45億 USD | 1.29億 USD | 1.81億 USD | 3459.7萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$49.00
上漲空間 28.17%報告持有此股票曝險的交易所交易基金。
Avantis U.S. Small Cap Value ETFAVUV1.07億0.35%308.51億 USD0.25%US$119.94+0.25%
Vanguard Morningstar Total Stock Market ETFVTI6129.9萬0.00%2.3兆 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM4747.56萬0.06%787.4億 USD0.19%US$277.9-0.37%
Vanguard Morningstar Small-Cap ETFVB4452.98萬0.02%1853億 USD0.03%US$288.16-0.46%
Fidelity Enhanced Small Cap ETFFESM3189.61萬0.48%64.1億 USD0.28%US$45.24-0.48%
Dimensional - US Targeted Value ETFDFAT2738.95萬0.09%301.22億 USD0.33%US$67.42+0.22%
Vanguard Morningstar Small-Cap Growth ETFVBK2552.97萬0.06%447億 USD0.05%US$340.88-1.12%
U.S. Small Cap Value Portfolio ETF Class SharesDFSV2119.33萬0.08%268.09億 USD0.33%US$37.98+0.08%Avantis U.S. Small Cap Value ETFAVUVVanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBFidelity Enhanced Small Cap ETFFESMDimensional - US Targeted Value ETFDFATVanguard Morningstar Small-Cap Growth ETFVBKU.S. Small Cap Value Portfolio ETF Class SharesDFSVAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
